C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting

Financial Review: C4 Therapeutics (NASDAQ:CCCC) and Alkermes (NASDAQ:ALKS)

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates